Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nouveaux Medical
Newport Beach, California, United Statesnouveaux.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nouveaux is a clinical-stage medical aesthetics company focused on developing next-generation botulinum toxin products. The company's lead candidate, NOU-001, is a premium botulinum toxin type A currently advancing into pivotal clinical trials for the treatment of glabellar lines. Led by a management team with deep expertise from industry leaders like Allergan and Evolus, Nouveaux aims to disrupt the neurotoxin market through scientific innovation and a provider-centric commercial model. In June 2024, the company announced a $130 million Series A financing round to fund the completion of its clinical programs and support its path toward regulatory approval and commercialization.
- Therapeutic areas
- Dermatology
- Modalities
- ProteinBotulinum toxin
- Industry
- Biotech
Beyond the preview
Go deeper on Nouveaux Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nouveaux Medical.